📇 Rhumatologue · VALENCIENNES CEDEX · (59) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
126.7 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CH VALENCIENNES
114 AV DESANDROUINS BP 479, 59322 VALENCIENNES CEDEX
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Pain practice : the official journal of World Institute of Pain · 2016
AbstractBackground/PurposeLittle information exists on the comparative patient and economic burden of chronic widespread pain (CWP) and fibromyalgia (FM) in the United States.MethodsThis multistage, observational study included an online screening survey of a large geographically diverse US sample to assess CWP status, a physician/site visit to determine FM diagnosis, and an online subject questionnaire to capture clinical characteristics, pain, health status, functioning, sleep, healthcare resource use (HRU), productivity, and costs. Based on the screener and physician evaluation, mutually exclusive groups of subjects without CWP (CWP−), with CWP but without FM (CWP+), and with confirmed FM were identified.ResultsDisease burden was examined in 472 subjects (125 CWP‐, 176 CWP+, 171 FM). Age, race, and ethnicity were similar across groups. Mean body mass index and number of comorbidities increased from CWP− to CWP+ to FM (P = 0.0044, P < 0.0001, respectively). From CWP− to CWP+ to FM, there were reductions in health status (EQ‐5D, SF‐12) and sleep outcomes (MOS‐SS, SSQ) (all P < 0.05). Pain severity, interference with function (BPI‐SF), and overall work impairment (WPAI:SHP) increased from CWP− to CWP+ to FM (all P < 0.0001). Higher proportions of CWP+ (52.8%) and FM subjects (62.6%) were taking pain‐related prescription medications relative to CWP− subjects (32.8%; P < 0.0001). Significant differences in total direct and indirect costs across the three groups (both P < 0.0001) were observed, with highest costs among FM subjects.ConclusionFibromyalgia subjects were characterized by the greatest disease burden with more comorbidities and pain‐related medications, poorer health status, function, sleep, lower productivity, and higher costs.
Dento maxillo facial radiology · 2013
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Current medical research and opinion · 2011 · Evaluation Study
Cryer B, Luo X, Assaf AR, Sands G, et al.
Dento maxillo facial radiology · 2013 · Journal Article
Assaf AT, Kahl-Nieke B, Feddersen J, Habermann CR
American health & drug benefits · 2017 · Journal Article
Assaf AR, Bushmakin AG, Joyce N, Louie MJ, et al.
Bulletin du cancer · 2025 · English Abstract
Assaf A, Forzy ML, Pétigny V, Poncelet E, et al.
Archives of internal medicine · 2005 · Clinical Trial
Brunner RL, Gass M, Aragaki A, Hays J, et al.
Pain practice : the official journal of World Institute of Pain · 2016 · Comparative Study
Schaefer C, Mann R, Masters ET, Cappelleri JC, et al.
BioMed research international · 2019 · Journal Article
Uzrail AH, Assaf AM, Abdalla SS
Archives of internal medicine · 2005 · Clinical Trial
Brunner RL, Gass M, Aragaki A, Hays J, et al.
Frontiers in immunology · 2015 · Journal Article
Musters A, Assaf A, Gerlag DM, Tak PP, et al.
Anticancer research · 2021 · Case Reports
König D, Sauvigny T, Brekenfeld C, Friedrich RE, et al.